Golden David B K, Kagey-Sobotka Anne, Norman Philip S, Hamilton Robert G, Lichtenstein Lawrence M
Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224, USA.
N Engl J Med. 2004 Aug 12;351(7):668-74. doi: 10.1056/NEJMoa022952.
Children are thought to "outgrow" the allergy to insect stings, but there are no reports documenting the natural history of this reaction. We studied the outcome of allergic reactions to insect stings in childhood 10 to 20 years afterward in patients who had not received venom immunotherapy and in those who had been treated.
Between 1978 and 1985, we diagnosed allergic reaction to insect stings in 1033 children, of whom 356 received venom immunotherapy. We conducted a survey of these patients by telephone and mail between January 1997 and January 2000, to determine the outcome of stings that occurred in the period from 1987 through 1999.
Of the 1033 patients, 512 patients (50 percent) responded, with a mean follow-up period of 18 years, a mean duration of venom immunotherapy of 3.5 years in treated patients, and an incidence of stings of 43 percent. Systemic reactions occurred less frequently in patients who had received venom immunotherapy (2 of 64 patients, or 3 percent) than in untreated patients (19 of 111 patients, or 17 percent; P=0.007). Patients with a history of moderate-to-severe reactions had a higher rate of reaction if they had not been treated (7 of 22 patients, or 32 percent) than if they had received venom immunotherapy (2 of 43 patients, or 5 percent; P=0.007). In patients who had been treated and who had a history of mild (cutaneous) systemic reaction (i.e., one with only cutaneous manifestations), none of the 21 subjects who received stings had a systemic reaction.
A clinically important number of children do not outgrow allergic reactions to insect stings. Venom immunotherapy in children leads to a significantly lower risk of systemic reaction to stings even 10 to 20 years after treatment is stopped, and this prolonged benefit is greater than the benefit seen in adults.
人们认为儿童会“摆脱”对昆虫叮咬的过敏,但尚无报告记录这种反应的自然病程。我们研究了未接受毒液免疫疗法的患者以及接受过治疗的患者在儿童期昆虫叮咬过敏反应10至20年后的转归情况。
1978年至1985年间,我们诊断出1033名儿童对昆虫叮咬过敏,其中356名接受了毒液免疫疗法。1997年1月至2000年1月期间,我们通过电话和邮件对这些患者进行了调查,以确定1987年至1999年期间发生的叮咬的转归情况。
1033名患者中,512名患者(50%)作出回应,平均随访期为18年,接受治疗的患者毒液免疫疗法的平均疗程为3.5年,叮咬发生率为43%。接受毒液免疫疗法的患者发生全身反应的频率(64名患者中有2名,即3%)低于未治疗的患者(111名患者中有19名,即17%;P=0.007)。有中度至重度反应史的患者若未接受治疗,其反应发生率(22名患者中有7名,即32%)高于接受毒液免疫疗法的患者(43名患者中有2名,即5%;P=0.007)。在接受过治疗且有轻度(皮肤性)全身反应史(即仅有皮肤表现)的患者中,接受叮咬的21名受试者均未发生全身反应。
相当数量的儿童不会摆脱对昆虫叮咬的过敏反应。儿童进行毒液免疫疗法即使在停止治疗10至20年后,也会显著降低叮咬引起全身反应的风险,且这种长期益处大于在成人中观察到的益处。